Get started Log in

6955 — Shandong Boan Biotechnology News Story

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Market Cap
HK$1.96bn
Enterprise Value
HK$1.66bn
Revenue
CNY784.82m

Brief: Shandong Boan Biotechnology Submits BLA For BA9101 To Anvisa In Brazil

Shandong Boan Biotechnology

05/08/2026 16:10

BRIEF-Shandong Boan Biotechnology Submits BLA For BA9101 To Anvisa In BrazilAug 5 (Reuters) - Shandong Boan Biotechnology Co Ltd 6955.HK:
SUBMITS BLA FOR BA9101 TO ANVISA IN BRAZIL
Further company coverage: 6955.HK

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Shandong Boan Biotechnology

Brief: Shandong Boan Biotechnology Says CDE Clears IND Application For BA1203
14/09/2026 18:20
Brief: Shandong Boan Biotechnology Co Says Industrial Bank Financial Leasing Will Purchase Leased Assets From Co
27/08/2026 17:09
Brief: Shandong Boan Biotechnology Announces CDE IND Application Acceptance For TLLA/IL-23 Bispecific Antibody BA2201
26/08/2026 17:09
Brief: Shandong Boan Biotechnology Expects Net Loss Attributable Of RMB79 Million-RMB89 Million
14/08/2026 15:17
Brief: Shandong Boan Biotechnology Submits BLA For BA9101 To Anvisa In Brazil
05/08/2026 16:10